ZYME
HealthcareZymeworks Inc. · Biotechnology · $2B
What is Zymeworks Inc.?
Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapies. Headquartered in Vancouver, Canada, the company is advancing a pipeline of bispecific antibodies and antibody-drug conjugates targeting multiple tumor types.
Zymeworks generates value through clinical development of engineered biotherapeutics and strategic licensing partnerships with major pharmaceutical companies. Rather than selling commercial products today, the company earns milestone payments and collaboration revenue while advancing its pipeline toward potential regulatory approval. Its partnerships with firms such as Eli Lilly, Bristol-Myers Squibb, and Daiichi Sankyo provide both funding and validation of its platform technology.
Zymeworks was incorporated in 2003 and operates out of Vancouver, Canada.
- Zanidatamab — a bispecific antibody in trials for biliary tract, gastroesophageal, breast, and colorectal cancers
- ZW49 — a biparatopic HER2-targeting antibody-drug conjugate in Phase 1 trials
- Proprietary bispecific antibody engineering platform licensed to multiple pharma partners
- Research collaborations in oncology and adjacent therapeutic areas
Is ZYME a Good Stock to Buy?
UQS Score rates ZYME as Below Average overall, reflecting the realities of clinical-stage biotech investing.
The Growth pillar stands out as the clearest bright spot, driven by an active clinical pipeline and expanding partnership network. The Risk pillar also rates favorably relative to many clinical-stage peers, suggesting the company's financial runway and risk management compare reasonably well within its cohort.
The Quality pillar is rated Weak, consistent with a pre-revenue company that has not yet demonstrated sustained profitability or cash generation.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ZYME pay dividends?
No — Zymeworks Inc. does not currently pay a dividend.
Zymeworks does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. Available capital is directed toward research, clinical trials, and partnership development rather than shareholder distributions. Income-focused investors should factor this into their assessment of ZYME.
When does ZYME report earnings?
Zymeworks reports financial results on a quarterly cadence, consistent with US- and Canadian-listed equities.
As a clinical-stage company, quarterly results are shaped primarily by collaboration revenue, milestone receipts, and research expenditure rather than product sales. Investors typically focus on pipeline progress and cash position updates rather than traditional earnings metrics.
For the most recent quarter's results and management commentary, visit Zymeworks' investor relations page directly.
ZYME Price History
-9.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Zymeworks Inc.?
Based on Zymeworks Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ZYME Long-term Outlook
Zymeworks' Growth pillar rating reflects a pipeline that is advancing through meaningful clinical milestones, with zanidatamab representing a potential near-term catalyst across several cancer indications. The Good Risk rating suggests the company maintains a relatively stable financial footing for a clinical-stage biotech. However, the path to commercialization remains long, and the Neutral Valuation label indicates the market has already priced in a degree of pipeline optionality.
Growth drivers
- Advancement of zanidatamab through late-stage clinical trials across multiple cancer types
- Milestone and royalty payments from an expanding network of major pharma partnerships
- Potential regulatory approvals unlocking commercial revenue for the first time
Key risks
- Clinical trial failure or delays could significantly reset growth expectations
- Pre-revenue status means continued dependence on partnership funding and capital markets
- Neutral Valuation suggests limited margin of safety if pipeline news disappoints
ZYME vs Peers
Zymeworks operates in a competitive clinical-stage oncology landscape alongside other specialty biopharmaceutical companies.
Agios focuses on cellular metabolism in cancer and rare diseases, with an approved commercial product giving it a different revenue profile than Zymeworks.
Mineralys is developing therapies targeting aldosterone-driven cardiovascular and cardiorenal diseases, representing a different therapeutic focus than Zymeworks' oncology pipeline.
Mesoblast pursues cell-based therapies for inflammatory and cardiovascular conditions, distinguishing it from Zymeworks' antibody-engineering approach to cancer.
Frequently Asked Questions
What does Zymeworks do?
Zymeworks is a clinical-stage biopharmaceutical company that engineers novel cancer therapies, including bispecific antibodies and antibody-drug conjugates. Its lead candidates target HER2-expressing tumors and several gastrointestinal and breast cancer indications. The company also licenses its platform technology to major pharmaceutical partners.
Does ZYME pay dividends?
No, Zymeworks does not currently pay a dividend. As a clinical-stage company, it reinvests available capital into research and clinical development. Dividend payments are unlikely until the company reaches sustained commercial revenue.
When does ZYME report earnings?
Zymeworks reports on a quarterly cadence. Because our data source does not cover specific upcoming dates, investors should check the company's investor relations page for the most current earnings schedule and recent results.
Is ZYME a good stock to buy?
UQS Score rates ZYME as Below Average overall. The Growth pillar is a clear strength, while the Quality pillar is Weak — reflecting the pre-revenue nature of the business. Whether ZYME fits a portfolio depends on an investor's risk tolerance and time horizon. View the full pillar breakdown on UQS Pro.
Is ZYME overvalued?
The UQS Valuation pillar for ZYME is rated Neutral, suggesting the market's current pricing neither represents a clear bargain nor an obvious premium relative to the company's stage and pipeline potential. Clinical-stage biotech valuations are inherently speculative and driven by trial outcomes.
How does ZYME compare to its competitors?
Compared to peers like Agios Pharmaceuticals and Mesoblast, Zymeworks is distinguished by its bispecific antibody engineering platform and deep oncology focus. Its broad partnership network with major pharma companies provides validation that some smaller clinical-stage peers lack. The UQS platform provides side-by-side pillar comparisons for subscribers.
What is ZYME's market cap bracket?
Zymeworks is classified as a mid-cap company. This places it above the micro- and small-cap clinical-stage biotechs but below large established pharmaceutical firms, reflecting its pipeline progress and partnership-backed valuation.
Who founded Zymeworks?
Zymeworks was incorporated in 2003. Founding and leadership history is publicly available through the company's official website and regulatory filings for investors who want the full historical context.
Is ZYME a long-term quality investment?
As a long-term quality indicator, ZYME's UQS profile is mixed. The Strong Growth pillar points to meaningful pipeline momentum, but the Weak Quality pillar reflects the absence of established profitability. Long-term quality typically improves as clinical milestones are achieved and revenue becomes more predictable.
What is the main competitive advantage of Zymeworks?
Zymeworks' core advantage lies in its proprietary antibody engineering platform, which enables the design of bispecific and biparatopic antibodies with differentiated mechanisms. This platform has attracted partnerships with several of the world's largest pharmaceutical companies, providing both credibility and non-dilutive funding.
Unlock Full ZYME Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics and trend data for Zymeworks
- ✓Compare ZYME side-by-side with clinical-stage biotech peers
- ✓Track pipeline and partnership developments through the UQS dashboard
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
ZYME — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 44.0 | 12.9 | 42.0 | 85.0 | 47.1 | 41.7 | -0.1 |
| May 21, 2026 | 44.1 | 12.9 | 42.0 | 85.0 | 47.1 | 42.0 | 0.0 |
| May 14, 2026 | 44.1 | 12.9 | 42.0 | 85.0 | 47.1 | 42.1 | -5.8 |
| May 8, 2026 | 49.9 | 12.9 | 42.0 | 85.0 | 64.7 | 62.8 | +1.5 |
| May 7, 2026 | 48.4 | 11.3 | 42.0 | 85.0 | 72.8 | 47.6 | -0.1 |
| May 3, 2026 | 48.5 | 11.3 | 42.0 | 85.0 | 72.8 | 48.3 | +0.2 |
| Apr 26, 2026 | 48.3 | 11.3 | 42.0 | 85.0 | 72.8 | 47.2 | -0.1 |
| Apr 19, 2026 | 48.4 | 11.3 | 42.0 | 85.0 | 72.8 | 47.5 | -0.1 |
| Apr 14, 2026 | 48.5 | 11.3 | 42.0 | 85.0 | 72.8 | 48.6 | 0.0 |
| Apr 12, 2026 | 48.5 | 11.3 | 42.0 | 85.0 | 72.8 | 48.5 | -0.1 |
ZYME — Pillar Breakdown
Quality
— 12.9/100 (25%)Zymeworks Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.0/100 (20%)Zymeworks Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 47.1/100 (15%)Zymeworks Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 41.7/100 (15%)Zymeworks Inc. has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Zymeworks Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ZYME.
Score Composition
Financial Data
More Stock Analysis
How is the ZYME UQS Score Calculated?
The UQS (Unified Quality Score) for Zymeworks Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Zymeworks Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Zymeworks Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.